RxDoctor Payments Data

Melhem Solh, MD

Hematology-Oncology · Atlanta, GANPI 1023282514

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $912,342 of the $1,148,374 with a category attached, or 79.4%. 49 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 24.1% of the total.

$1,148,374in general payments, 2019–2025

Across 1,125 payments — averaging $1020.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$277K
  • GSK$233K
  • Amgen$96K
  • Bristol Myers Squibb$95K
  • Seagen Inc.$92K
  • Sanofi$68K
  • plus $286K from 43 others
$3,171,347in research payments, 2019–2025

Across 134 payments — averaging $23,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2.5M
  • Partner Therapeutics, Inc.$279K
  • Astellas Pharma Global Development$142K
  • ADC Therapeutics America, Inc.$135K
  • Trillium Therapeutics USA, LLC$81K
  • Merck$47K
  • plus $28K from 1 others

What the payments were for

  • Consulting fees$95,7988%
  • Speaking & faculty fees$912,34279%
  • Travel & lodging$107,4049%
  • Food & beverage$32,4233%
  • Education$4080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology-oncology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$95,632
Medicare patients
192
Services billed
3,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate33$551,084
RezurockBelumosudil Mesylate11$267,157
CresembaIsavuconazonium Sulfate24$151,138
Posaconazole24$21,683
Atovaquone12$8,646
EliquisApixaban12$7,768
Acyclovir146$2,270
Potassium Chloride40$540
Fluconazole18$536
Levofloxacin43$297
Prochlorperazine Maleate23$269
Pantoprazole Sodium42$235
Ondansetron Hcl38$194
Dexamethasone16$182
Gabapentin25$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$289$551,08433 claims
Sanofi-aventis U.S. LLCRezurock$207$267,15711 claims
Astellas Pharma US IncCresemba$875$151,13824 claims
PfizerEliquis$12,185$7,76812 claims
Lilly USA, LLCOlanzapine$94$6312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other hematology-oncology in Atlanta

Where these figures come from

Is this you, or does something look wrong? →